What Recent Research Reveals About the Brain, Body, and New Options in Midlife
Credit: Daily Vitality
For a long time, perimenopause was treated like a rumor. You felt the shifts, the wakeful nights, the aching hands, the fog that rolled in mid-sentence, and yet the science had surprisingly little to say about any of it. That is changing fast. Over the past two years, researchers have turned real attention toward the years leading up to menopause, and the picture emerging is far more interesting, and far more validating, than the old "it's just your hormones" shrug.
Part of what is driving the interest is scale. Menopause symptoms are now estimated to cost around $1.8 billion in lost work productivity each year in the United States, according to a Mayo Clinic analysis, with roughly 600,000 women stepping back from work because of severe symptoms. When something affects that many people that deeply, it eventually gets studied properly. And it is.
So we went looking for what the newest research actually shows. Below are 10 findings that stood out, chosen because they are recent, credible, and genuinely change how we understand this stage of life. Some are reassuring, some are surprising, and a few point to brand-new options that simply did not exist a couple of years ago. None of this is medical advice, and every woman's experience is her own, but knowing what the evidence says can make the whole transition feel a little less mysterious.
If perimenopause has ever left you searching for a word that was right there a second ago, here is something worth knowing: that fog appears to have a physical basis. A review of brain-imaging research presented at The Menopause Society's 2025 annual meeting found that the menopause transition is associated with distinct structural changes, including reductions in gray matter volume in the frontal and temporal regions and the hippocampus, the parts of the brain most involved in memory and clear thinking, as summarized by The Menopause Society.
The same body of work has also documented more white matter hyperintensities, small bright spots on brain scans that reflect changes in the brain's tiny blood vessels, particularly in women with early menopause or frequent hot flashes. It is a reminder that brain health and vascular health are closely linked during this stage, which is part of why several of the findings later in this list keep circling back to the heart. If the fog itself is what weighs on you most, it can help to understand what drives perimenopause brain fog and the everyday ways women ease it.
Here is the hopeful part, though. Some of that gray matter appears to partially recover after menopause, which researchers interpret as the brain adapting and reorganizing rather than simply declining. Federally funded imaging research described by the National Institute on Aging points the same way, suggesting menopause affects the brain as its own event, separate from ordinary aging. As Dr. Stephanie Faubion, medical director of The Menopause Society, has framed it, this reflects the cumulative body of scientific knowledge on how the brain changes during this transition. In other words, the fog is real, it is measurable, and it is not necessarily permanent.
For anyone who has been told their tearfulness or irritability is simply stress, the research offers some overdue validation. A large 2024 review of long-term studies following more than 16,000 women found that those in perimenopause had roughly a 40% higher likelihood of depression compared with premenopausal women, as reported in the Journal of Affective Disorders. Because these were studies that tracked women over time, the finding carries more weight than a single snapshot, and the elevated risk held up even after accounting for things like age and life circumstances.
The pattern shows up at the more serious end too. Drawing on health records from more than 128,000 women, a study in Nature Mental Health found that the perimenopausal years were linked with a rise in first-time diagnoses of major depression, and even mania and schizophrenia-spectrum conditions, compared with the late reproductive stage. For any individual the absolute risk stays low, but the signal is meaningful enough that new or worsening mood symptoms in your 40s and 50s deserve to be taken seriously rather than waved off.
If you are experiencing thoughts of self-harm or a mental-health crisis, please reach out to a qualified professional or a crisis line right away. In the United States, you can call or text 988 to reach the Suicide and Crisis Lifeline. Perimenopause-related mood changes are real, and support is available.
That last point matters because women in this stage are sometimes misread. In-depth 2025 interviews with women who experienced serious mental-health struggles during the transition found that many were told they simply had anxiety or depression, with no one connecting the dots to menopause. Naming the transition as a possible factor is often the first step toward getting the right kind of help. It can also help to understand why anxiety tends to intensify in perimenopause and what tends to soothe it.
If your joints started speaking up somewhere around your mid-40s, you are in very good company, and there is now language for it. A 2024 review in the journal Climacteric introduced the term "musculoskeletal syndrome of menopause" to describe a cluster of estrogen-related changes in midlife, including joint pain, muscle aches, stiffness, loss of muscle strength, and faster bone loss. Giving it a name does something quietly powerful: it turns a scattered list of complaints into a recognized pattern you can actually bring to an appointment.
The reason the aches show up seemingly everywhere at once comes down to biology. Estrogen receptors are woven throughout the musculoskeletal system, in bone, tendon, muscle, cartilage, and ligament, so when estrogen declines, the effects ripple across the whole movement system rather than staying in one spot. That is why you might feel it in your knees, your hands, and your shoulders in the same season.
And it is common. An overview from Harvard Health estimates that around 70% of women experience musculoskeletal symptoms during peri- and postmenopause, and roughly one in four have symptoms significant enough to be genuinely limiting.
Frozen shoulder, which mostly affects women in their 40s and 50s, may fit this picture as well. Early evidence from a Duke Health analysis suggests women using hormone therapy had somewhat less shoulder pain, though the link did not reach statistical significance and researchers are still studying it. It is a lead worth watching, not a conclusion to act on alone.
This one asks for a careful read, because it is fascinating and easily misunderstood. Researchers measuring hot flashes objectively during sleep, rather than relying on next-morning memory, found that night sweats were associated with less favorable Alzheimer's-related markers in the blood, specifically in the ratio of certain amyloid proteins, in work published in the American Journal of Obstetrics & Gynecology. Notably, the association held even after the researchers accounted for how well the women slept, which suggests the nighttime hot flashes themselves, not just the resulting poor sleep, may be the relevant signal.
It is important to be clear about what this does and does not mean. This is an association with a biomarker, not evidence that night sweats cause Alzheimer's disease, and it is certainly not a diagnosis. What it does is help explain why clinicians are starting to pay closer attention to vasomotor symptoms, the medical term for hot flashes and night sweats, as a possible flag for who might benefit from more proactive brain-health monitoring down the line.
"Vasomotor symptoms" simply means hot flashes and night sweats. You will see the phrase throughout menopause research, and it covers the same experiences you already know well.
If your nights have been drenched and disrupted, the takeaway is not alarm. It is that these symptoms are worth mentioning to your clinician as part of the bigger health conversation, rather than quietly enduring them.
Hot flashes have long been filed under "uncomfortable but harmless." The newer research suggests they may carry more information than that. A feature in MDedge reviewing multiple studies described frequent or severe hot flashes as an emerging, subclinical cardiovascular risk factor, with research connecting them to higher C-reactive protein, a marker of inflammation, along with changes in blood vessel function and blood pressure, especially when the hot flashes disrupt sleep.
Because some of this evidence comes from conference presentations and observational work, the honest framing is "associated with" rather than "causes." Still, the direction is consistent enough that experts increasingly suggest a woman's hot flash history belongs in the conversation when assessing heart health in midlife.
The practical reframe is a kind one. Instead of viewing hot flashes as something to simply outlast, you might view frequent ones as a gentle prompt to check in on the rest of your cardiovascular picture, blood pressure, cholesterol, and the everyday habits that support your heart. It turns an unwelcome symptom into a piece of useful, actionable information.
Here is a finding that is genuinely current. On October 24, 2025, the FDA approved elinzanetant, sold under the brand name Lynkuet, as a non-hormonal treatment for moderate-to-severe hot flashes and night sweats due to menopause, as reported by the American Journal of Managed Care. What makes it notable is how it works. Rather than replacing estrogen, it targets the brain's internal thermostat directly, making it an option for women who cannot or would prefer not to take hormones.
The approval rested on a series of phase 3 trials known as the OASIS studies. In that research, elinzanetant produced meaningful reductions in both how often hot flashes happened and how intense they were compared with placebo, with benefits appearing within about four weeks and holding steady through at least 12 weeks, alongside improvements in sleep and overall quality of life. It is the second drug in this new non-hormonal class to reach the market, following an earlier medication that works on a similar brain pathway.
The broader point is bigger than any single prescription. New, well-studied treatments arriving in late 2025 are a sign that perimenopause research is no longer stuck, and that the menu of options is expanding. It is far from the only recent approval, either, and it is worth knowing about the other FDA-approved medications quietly reshaping perimenopause care. Whether any of them is a good fit is a personal decision to weigh with a clinician, but it is encouraging simply to know the menu is growing.
If you formed your impression of hormone therapy from headlines two decades ago, it may be worth a fresh look. The current thinking centers on what researchers call the "timing hypothesis," and an explainer from the American Journal of Managed Care describes it well: starting hormone therapy before age 60 or within about 10 years of menopause tends to be associated with a more favorable risk-benefit picture than starting it much later.
Major cardiology voices have echoed this shift. A review in the American Heart Association's journal Circulation concluded that for many healthy women under 60 or within a decade of menopause, systemic hormone therapy has a generally reasonable benefit-risk balance for managing symptoms, while noting that lower-dose and skin-based (transdermal) approaches are often preferred when heart or metabolic risks are a consideration.
This is a real evolution from the broad-brush worry that followed early 2000s research, which grouped women of very different ages and risk profiles together. The modern message is more individualized: the answer depends on your age, your timing, your health history, and how a therapy is delivered. That is not a green light or a red light. It is an invitation to have a more informed, personalized conversation with your clinician rather than ruling anything in or out based on old headlines.
Few things are more frustrating than doing everything the same and watching your body respond differently, especially around the middle. The research is clear that this is not a character flaw. Long-term data on the menopause transition, summarized in work hosted by the National Library of Medicine, shows that total and activity-related energy expenditure tends to decline as women move from premenopause through perimenopause, while visceral fat, the deeper fat stored around the abdominal organs, tends to increase.
That shift toward abdominal fat matters for more than how clothes fit, because visceral fat is metabolically active and is linked with higher risks to heart and metabolic health. And crucially, this recalibration begins during perimenopause, not only after periods stop, which is why the changes can feel like they arrive without warning.
Understanding the mechanism is genuinely freeing, because it moves the story away from blame. It also points toward what tends to help most in this stage, things like building and preserving muscle through strength work, prioritizing protein, and keeping an eye on the cardiometabolic markers your clinician can check. Nutrition plays a supporting role too, and it can be useful to know which foods are especially worth leaning on during perimenopause. The goal shifts from fighting your body to working with its new chemistry.
One of the most persistent myths is that perimenopause is strictly a late-40s event. A 2025 analysis drawing on the Apple Women's Health Study challenges that directly. Among more than 4,400 participants who identified as experiencing perimenopause, more than half of those aged 30 to 35 reported moderate or severe symptoms, including hot flashes, irritability, mental exhaustion, and changes in sexual health, as published in npj Women's Health. These are self-reported symptoms rather than confirmed hormonal diagnoses, but the sheer number is striking, and it validates younger women who have been told they are imagining things.
The wearable data tells a similar story about sleep. Researchers at the Harvard T.H. Chan School of Public Health found that in the roughly 18 months before the final period, about 60% of participants showed more nighttime wakefulness, measured objectively as time spent awake after first falling asleep. In other words, the restless nights so many women describe are visible in the data, and they ramp up well before menopause becomes "official."
The reassurance here is about being believed. If your body has been sending signals earlier than the textbooks suggested, the newest research is on your side, and it may be worth raising with a clinician even if you feel younger than the stereotype. It can also help to set expectations by seeing how long perimenopause typically lasts and what the timeline looks like.
Saving one of the most under-discussed findings for last: many women notice their focus, organization, and emotional steadiness wobble during perimenopause, and there is emerging research to match. A 2025 study in the Journal of Attention Disorders found that women with higher levels of ADHD-type symptoms tended to report more severe menopausal symptoms and greater day-to-day difficulty during the transition.
The likely mechanism is elegant once you see it. Estrogen helps regulate dopamine, the brain chemical tied to attention and motivation, so as estrogen fluctuates and declines, the systems that support focus and impulse control can waver too. For some women this intensifies ADHD they already knew about. For others, it surfaces attention challenges that had been quietly managed for decades, prompting the very relatable question, "Wait, could this have been me all along?"
This is an early and actively growing area of research, and much of the current evidence comes from self-reported surveys, so it is best held as a promising lens rather than a settled rule. Still, it connects two experiences women rarely hear discussed together, and simply knowing the link exists can make a foggy, scattered season feel less like a personal failing and more like something with a name and a reason.
Taken together, these 10 findings point to the same reassuring idea: what you are feeling is real, it is being studied, and you have more understanding and more options than women did even a few years ago. If you want the fuller picture of the transition itself, it helps to step back and see what is actually happening in your body during your 40s. Knowledge really is the gentlest form of relief here, and there is more of it than ever.
About the Author
Angela Nightingale is a Senior Editor at Daily Vitality with over two decades of experience in digital publishing and health and wellness content. She specializes in turning complex, often-confusing health topics into clear, calm, and practical guidance that respects the reader's intelligence. Her work focuses on helping people feel informed and confident — never overwhelmed or alarmed — as they make everyday decisions about how they eat, move, rest, and age.
Perimenopause is the transition leading up to menopause, when hormone levels fluctuate and symptoms often begin. Menopause itself is a single point in time, marked once you have gone 12 consecutive months without a period. The years after that are called postmenopause.
It varies widely. While many people associate it with the late 40s, research from the Apple Women's Health Study found that more than half of participants aged 30 to 35 reported moderate or severe symptoms, so starting in your 30s is more common than the stereotype suggests.
Current evidence is reassuring. Imaging research links brain fog to measurable changes during the transition, but some of those changes appear to partially recover afterward, which researchers interpret as the brain adapting rather than simply declining.
Hot flashes are not inherently dangerous, but frequent or severe ones are increasingly viewed as a possible clue about heart and brain health. Rather than a cause for alarm, they can be a useful prompt to check in on your overall cardiovascular picture with a clinician.
Estrogen receptors are found throughout bone, muscle, tendon, cartilage, and ligament, so declining estrogen can affect the whole movement system. Researchers have named this pattern the "musculoskeletal syndrome of menopause," and it affects an estimated 70% of women during the transition.
The answer has become more nuanced. For many healthy women under 60 or within about 10 years of menopause, experts describe a generally favorable balance of benefits and risks for symptom relief, with the specifics depending on your health history, timing, dose, and how the therapy is delivered. It is a personalized decision to make with a clinician.
Elinzanetant (brand name Lynkuet) is a non-hormonal medication the FDA approved in October 2025 for moderate-to-severe hot flashes. Instead of replacing estrogen, it works on the brain pathways that regulate body temperature, which makes it an option for women who cannot or prefer not to use hormones.
During the transition, energy expenditure tends to decline and fat tends to redistribute toward the abdomen, driven by hormonal changes rather than willpower. Strength training, adequate protein, and monitoring cardiometabolic markers are commonly discussed ways to work with these shifts.
Emerging research suggests it can. Because estrogen helps regulate dopamine, fluctuating levels can affect attention and emotional regulation, intensifying existing ADHD or surfacing attention difficulties for the first time. It is an early but growing area of study.
There is no wrong time. If symptoms are affecting your sleep, mood, focus, comfort, or daily life, or if you are simply unsure whether what you are feeling is related to the transition, that is reason enough to start a conversation and explore your options.
